1. Home
  2. NAMSW vs PFLT Comparison

NAMSW vs PFLT Comparison

Compare NAMSW & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • PFLT
  • Stock Information
  • Founded
  • NAMSW N/A
  • PFLT N/A
  • Country
  • NAMSW Netherlands
  • PFLT United States
  • Employees
  • NAMSW 29
  • PFLT N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • PFLT Finance: Consumer Services
  • Sector
  • NAMSW Health Care
  • PFLT Finance
  • Exchange
  • NAMSW Nasdaq
  • PFLT Nasdaq
  • Market Cap
  • NAMSW N/A
  • PFLT N/A
  • IPO Year
  • NAMSW N/A
  • PFLT N/A
  • Fundamental
  • Price
  • NAMSW $9.12
  • PFLT $11.40
  • Analyst Decision
  • NAMSW
  • PFLT Buy
  • Analyst Count
  • NAMSW 0
  • PFLT 1
  • Target Price
  • NAMSW N/A
  • PFLT $12.50
  • AVG Volume (30 Days)
  • NAMSW N/A
  • PFLT 750.3K
  • Earning Date
  • NAMSW N/A
  • PFLT 08-07-2024
  • Dividend Yield
  • NAMSW N/A
  • PFLT 10.78%
  • EPS Growth
  • NAMSW N/A
  • PFLT N/A
  • EPS
  • NAMSW N/A
  • PFLT 1.54
  • Revenue
  • NAMSW N/A
  • PFLT $155,774,000.00
  • Revenue This Year
  • NAMSW N/A
  • PFLT $14.65
  • Revenue Next Year
  • NAMSW N/A
  • PFLT $23.17
  • P/E Ratio
  • NAMSW N/A
  • PFLT $7.44
  • Revenue Growth
  • NAMSW N/A
  • PFLT 29.37
  • 52 Week Low
  • NAMSW N/A
  • PFLT $9.69
  • 52 Week High
  • NAMSW N/A
  • PFLT $12.63
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 40.67
  • PFLT 42.56
  • Support Level
  • NAMSW $9.40
  • PFLT $11.36
  • Resistance Level
  • NAMSW $10.14
  • PFLT $12.02
  • Average True Range (ATR)
  • NAMSW 0.33
  • PFLT 0.15
  • MACD
  • NAMSW -0.12
  • PFLT -0.04
  • Stochastic Oscillator
  • NAMSW 0.00
  • PFLT 10.61

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: